This trial is active, not recruiting.

Condition nasopharyngeal carriage of s. pneumoniae
Sponsor Boston Medical Center
Collaborator Thrasher Research Fund
Start date April 2010
End date October 2012
Trial size 5000 participants
Trial identifier NCT01109108, H-28757


The specific aim is to evaluate the impact of PCV13 as administered in the pediatric primary care clinic at Boston medical center on the serotype specific carriage of Streptococcus pneumoniae in children < 5 and their parents.

Specifically the investigators will measure the decline in vaccine serotypes, the proportion of children receiving vaccine required to achieve 50% reduction in serotype specific carriage and the correlation between immunogenicity of the specific serotypes and decline in carriage.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Time perspective prospective
children less than 2 years of age
children 2-5 years of age
parents of children

Primary Outcomes

serotype specific colonization with S. pneumoniae
time frame: 2 years

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - children < 5 years of age receiving care at Primary Care center at BMC and as many parent(s) as willing to participate Exclusion Criteria: - children with facial malformations making NP sampling unacceptable

Additional Information

Official title Streptococcus Pneumonia: Herd Effects and Emergence of Potentially Virulent Serotypes PCV13_Impact of NP Colonization, Herd Effects and Emergence of Potentially Virulent Serotypes of Pneumococci
Trial information was received from ClinicalTrials.gov and was last updated in November 2010.
Information provided to ClinicalTrials.gov by Boston Medical Center.